nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—NISCH—Paclitaxel—Docetaxel—melanoma	0.0385	1	CbGdCrCtD
Phentolamine—Tenderness—Bleomycin—melanoma	0.00905	0.0351	CcSEcCtD
Phentolamine—Injection site pain—Carmustine—melanoma	0.00844	0.0327	CcSEcCtD
Phentolamine—Injection site reaction—Carmustine—melanoma	0.00685	0.0266	CcSEcCtD
Phentolamine—Cardiac disorder—Vemurafenib—melanoma	0.00608	0.0236	CcSEcCtD
Phentolamine—Angiopathy—Vemurafenib—melanoma	0.00594	0.023	CcSEcCtD
Phentolamine—Mediastinal disorder—Vemurafenib—melanoma	0.0059	0.0229	CcSEcCtD
Phentolamine—Nasal congestion—Temozolomide—melanoma	0.00531	0.0206	CcSEcCtD
Phentolamine—Nervous system disorder—Vemurafenib—melanoma	0.00456	0.0177	CcSEcCtD
Phentolamine—Blood pressure increased—Docetaxel—melanoma	0.00443	0.0172	CcSEcCtD
Phentolamine—Injection site reaction—Docetaxel—melanoma	0.0044	0.0171	CcSEcCtD
Phentolamine—Acute coronary syndrome—Bleomycin—melanoma	0.00436	0.0169	CcSEcCtD
Phentolamine—Hypotension—Vemurafenib—melanoma	0.00435	0.0169	CcSEcCtD
Phentolamine—Myocardial infarction—Bleomycin—melanoma	0.00433	0.0168	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00402	0.0156	CcSEcCtD
Phentolamine—Flushing—Bleomycin—melanoma	0.00368	0.0143	CcSEcCtD
Phentolamine—Flushing—Dactinomycin—melanoma	0.00343	0.0133	CcSEcCtD
Phentolamine—Asthenia—Vemurafenib—melanoma	0.00334	0.0129	CcSEcCtD
Phentolamine—Pruritus—Vemurafenib—melanoma	0.00329	0.0128	CcSEcCtD
Phentolamine—Flushing—Carmustine—melanoma	0.00321	0.0125	CcSEcCtD
Phentolamine—Diarrhoea—Vemurafenib—melanoma	0.00318	0.0123	CcSEcCtD
Phentolamine—Flushing—Temozolomide—melanoma	0.0031	0.012	CcSEcCtD
Phentolamine—Cardiac disorder—Temozolomide—melanoma	0.0031	0.012	CcSEcCtD
Phentolamine—Arrhythmia—Carmustine—melanoma	0.00309	0.012	CcSEcCtD
Phentolamine—Dizziness—Vemurafenib—melanoma	0.00308	0.0119	CcSEcCtD
Phentolamine—Angiopathy—Temozolomide—melanoma	0.00304	0.0118	CcSEcCtD
Phentolamine—Mediastinal disorder—Temozolomide—melanoma	0.00302	0.0117	CcSEcCtD
Phentolamine—Vomiting—Vemurafenib—melanoma	0.00296	0.0115	CcSEcCtD
Phentolamine—Chest pain—Bleomycin—melanoma	0.00294	0.0114	CcSEcCtD
Phentolamine—Orthostatic hypotension—Docetaxel—melanoma	0.00294	0.0114	CcSEcCtD
Phentolamine—Abdominal pain upper—Docetaxel—melanoma	0.00294	0.0114	CcSEcCtD
Phentolamine—Headache—Vemurafenib—melanoma	0.00291	0.0113	CcSEcCtD
Phentolamine—Nausea—Vemurafenib—melanoma	0.00276	0.0107	CcSEcCtD
Phentolamine—Angina pectoris—Docetaxel—melanoma	0.00271	0.0105	CcSEcCtD
Phentolamine—Hypotension—Bleomycin—melanoma	0.00263	0.0102	CcSEcCtD
Phentolamine—Hypertension—Carmustine—melanoma	0.0026	0.0101	CcSEcCtD
Phentolamine—Chest pain—Carmustine—melanoma	0.00257	0.00995	CcSEcCtD
Phentolamine—Paraesthesia—Bleomycin—melanoma	0.00253	0.00981	CcSEcCtD
Phentolamine—Hypertension—Temozolomide—melanoma	0.00251	0.00975	CcSEcCtD
Phentolamine—Acute coronary syndrome—Docetaxel—melanoma	0.00244	0.00947	CcSEcCtD
Phentolamine—Myocardial infarction—Docetaxel—melanoma	0.00243	0.00942	CcSEcCtD
Phentolamine—Pain—Bleomycin—melanoma	0.00241	0.00934	CcSEcCtD
Phentolamine—Tachycardia—Carmustine—melanoma	0.0024	0.00931	CcSEcCtD
Phentolamine—Nervous system disorder—Temozolomide—melanoma	0.00233	0.00904	CcSEcCtD
Phentolamine—Hypotension—Carmustine—melanoma	0.0023	0.00891	CcSEcCtD
Phentolamine—Pain—Dactinomycin—melanoma	0.00225	0.00872	CcSEcCtD
Phentolamine—Paraesthesia—Carmustine—melanoma	0.00221	0.00856	CcSEcCtD
Phentolamine—Gastrointestinal pain—Dactinomycin—melanoma	0.00215	0.00833	CcSEcCtD
Phentolamine—Paraesthesia—Temozolomide—melanoma	0.00213	0.00828	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Carmustine—melanoma	0.00212	0.00823	CcSEcCtD
Phentolamine—Pain—Carmustine—melanoma	0.0021	0.00816	CcSEcCtD
Phentolamine—Abdominal pain—Dactinomycin—melanoma	0.00208	0.00806	CcSEcCtD
Phentolamine—Flushing—Docetaxel—melanoma	0.00206	0.00801	CcSEcCtD
Phentolamine—Cardiac disorder—Docetaxel—melanoma	0.00206	0.00801	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Temozolomide—melanoma	0.00205	0.00796	CcSEcCtD
Phentolamine—Pain—Temozolomide—melanoma	0.00203	0.00788	CcSEcCtD
Phentolamine—Asthenia—Bleomycin—melanoma	0.00202	0.00784	CcSEcCtD
Phentolamine—Angiopathy—Docetaxel—melanoma	0.00202	0.00783	CcSEcCtD
Phentolamine—Gastrointestinal pain—Carmustine—melanoma	0.00201	0.0078	CcSEcCtD
Phentolamine—Mediastinal disorder—Docetaxel—melanoma	0.00201	0.00778	CcSEcCtD
Phentolamine—Pruritus—Bleomycin—melanoma	0.00199	0.00773	CcSEcCtD
Phentolamine—Arrhythmia—Docetaxel—melanoma	0.00199	0.00771	CcSEcCtD
Phentolamine—Abdominal pain—Carmustine—melanoma	0.00194	0.00754	CcSEcCtD
Phentolamine—Gastrointestinal pain—Temozolomide—melanoma	0.00194	0.00754	CcSEcCtD
Phentolamine—Asthenia—Dactinomycin—melanoma	0.00189	0.00731	CcSEcCtD
Phentolamine—Abdominal pain—Temozolomide—melanoma	0.00188	0.00729	CcSEcCtD
Phentolamine—Diarrhoea—Dactinomycin—melanoma	0.0018	0.00697	CcSEcCtD
Phentolamine—Vomiting—Bleomycin—melanoma	0.00179	0.00695	CcSEcCtD
Phentolamine—Asthenia—Carmustine—melanoma	0.00176	0.00684	CcSEcCtD
Phentolamine—Asthenia—Temozolomide—melanoma	0.00171	0.00661	CcSEcCtD
Phentolamine—Diarrhoea—Carmustine—melanoma	0.00168	0.00653	CcSEcCtD
Phentolamine—Pruritus—Temozolomide—melanoma	0.00168	0.00652	CcSEcCtD
Phentolamine—Nausea—Bleomycin—melanoma	0.00167	0.00649	CcSEcCtD
Phentolamine—Hypertension—Docetaxel—melanoma	0.00167	0.00648	CcSEcCtD
Phentolamine—Vomiting—Dactinomycin—melanoma	0.00167	0.00648	CcSEcCtD
Phentolamine—Chest pain—Docetaxel—melanoma	0.00165	0.00639	CcSEcCtD
Phentolamine—Dizziness—Carmustine—melanoma	0.00163	0.00631	CcSEcCtD
Phentolamine—Diarrhoea—Temozolomide—melanoma	0.00163	0.00631	CcSEcCtD
Phentolamine—Dizziness—Temozolomide—melanoma	0.00157	0.0061	CcSEcCtD
Phentolamine—Vomiting—Carmustine—melanoma	0.00156	0.00606	CcSEcCtD
Phentolamine—Nausea—Dactinomycin—melanoma	0.00156	0.00605	CcSEcCtD
Phentolamine—Nervous system disorder—Docetaxel—melanoma	0.00155	0.00601	CcSEcCtD
Phentolamine—Tachycardia—Docetaxel—melanoma	0.00154	0.00598	CcSEcCtD
Phentolamine—Headache—Carmustine—melanoma	0.00154	0.00598	CcSEcCtD
Phentolamine—Vomiting—Temozolomide—melanoma	0.00151	0.00586	CcSEcCtD
Phentolamine—Headache—Temozolomide—melanoma	0.00149	0.00577	CcSEcCtD
Phentolamine—Hypotension—Docetaxel—melanoma	0.00148	0.00573	CcSEcCtD
Phentolamine—Nausea—Carmustine—melanoma	0.00146	0.00567	CcSEcCtD
Phentolamine—Paraesthesia—Docetaxel—melanoma	0.00142	0.0055	CcSEcCtD
Phentolamine—Nausea—Temozolomide—melanoma	0.00141	0.00548	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Docetaxel—melanoma	0.00136	0.00529	CcSEcCtD
Phentolamine—Pain—Docetaxel—melanoma	0.00135	0.00524	CcSEcCtD
Phentolamine—Gastrointestinal pain—Docetaxel—melanoma	0.00129	0.00501	CcSEcCtD
Phentolamine—Abdominal pain—Docetaxel—melanoma	0.00125	0.00485	CcSEcCtD
Phentolamine—Asthenia—Docetaxel—melanoma	0.00113	0.0044	CcSEcCtD
Phentolamine—Pruritus—Docetaxel—melanoma	0.00112	0.00434	CcSEcCtD
Phentolamine—Diarrhoea—Docetaxel—melanoma	0.00108	0.00419	CcSEcCtD
Phentolamine—Dizziness—Docetaxel—melanoma	0.00105	0.00405	CcSEcCtD
Phentolamine—Vomiting—Docetaxel—melanoma	0.001	0.0039	CcSEcCtD
Phentolamine—Headache—Docetaxel—melanoma	0.00099	0.00384	CcSEcCtD
Phentolamine—Nausea—Docetaxel—melanoma	0.000939	0.00364	CcSEcCtD
Phentolamine—ADRA2C—Metabolism—PIK3CB—melanoma	5.78e-05	8.22e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IGF1—melanoma	5.78e-05	8.21e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—AKT1—melanoma	5.77e-05	8.2e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—FN1—melanoma	5.76e-05	8.19e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—MAPK1—melanoma	5.75e-05	8.17e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—EGFR—melanoma	5.75e-05	8.17e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CB—melanoma	5.73e-05	8.15e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTGS2—melanoma	5.73e-05	8.14e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IGF1—melanoma	5.69e-05	8.08e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—FGF2—melanoma	5.69e-05	8.08e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—MAPK1—melanoma	5.66e-05	8.04e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—EGFR—melanoma	5.66e-05	8.04e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NOTCH1—melanoma	5.64e-05	8.02e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MAP2K1—melanoma	5.58e-05	7.94e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KDR—melanoma	5.56e-05	7.91e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CD—melanoma	5.55e-05	7.88e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CD80—melanoma	5.53e-05	7.85e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CG—melanoma	5.52e-05	7.84e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—APC—melanoma	5.52e-05	7.84e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—KIT—melanoma	5.52e-05	7.84e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—NRAS—melanoma	5.52e-05	7.84e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CXCL8—melanoma	5.51e-05	7.83e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MAP2K1—melanoma	5.5e-05	7.81e-05	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—PIK3CA—melanoma	5.49e-05	7.81e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—HRAS—melanoma	5.47e-05	7.78e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CD—melanoma	5.46e-05	7.76e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGF—melanoma	5.45e-05	7.75e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—KRAS—melanoma	5.43e-05	7.72e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—PIK3CA—melanoma	5.41e-05	7.69e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CD—melanoma	5.39e-05	7.66e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CDKN1B—melanoma	5.38e-05	7.65e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—FN1—melanoma	5.36e-05	7.61e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—KRAS—melanoma	5.35e-05	7.6e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—PIK3CA—melanoma	5.34e-05	7.59e-05	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—AKT1—melanoma	5.32e-05	7.56e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MDM2—melanoma	5.32e-05	7.56e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—ALB—melanoma	5.32e-05	7.56e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—FGF2—melanoma	5.31e-05	7.55e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—MAPK3—melanoma	5.28e-05	7.51e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CASP3—melanoma	5.27e-05	7.49e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL2—melanoma	5.27e-05	7.48e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ERBB2—melanoma	5.25e-05	7.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NOTCH1—melanoma	5.24e-05	7.45e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—IL6—melanoma	5.24e-05	7.45e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—FGF2—melanoma	5.23e-05	7.43e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—BRAF—melanoma	5.19e-05	7.37e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CB—melanoma	5.18e-05	7.36e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CD80—melanoma	5.13e-05	7.3e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCND1—melanoma	5.13e-05	7.29e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CG—melanoma	5.13e-05	7.28e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APC—melanoma	5.13e-05	7.28e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KIT—melanoma	5.13e-05	7.28e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—NRAS—melanoma	5.13e-05	7.28e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CTNNB1—melanoma	5.08e-05	7.22e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGF—melanoma	5.07e-05	7.2e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IGF1—melanoma	5.05e-05	7.18e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—MAPK1—melanoma	5.03e-05	7.14e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—EGFR—melanoma	5.03e-05	7.14e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTEN—melanoma	5e-05	7.1e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—PIK3CA—melanoma	4.99e-05	7.09e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MMP9—melanoma	4.98e-05	7.08e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CXCL8—melanoma	4.97e-05	7.07e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MDM2—melanoma	4.97e-05	7.06e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CDKN1A—melanoma	4.97e-05	7.06e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PTEN—melanoma	4.95e-05	7.04e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—HRAS—melanoma	4.94e-05	7.02e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NFKB1—melanoma	4.93e-05	7.01e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	4.91e-05	6.98e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—MAPK3—melanoma	4.91e-05	6.98e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ERBB2—melanoma	4.9e-05	6.96e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MDM2—melanoma	4.89e-05	6.95e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MAP2K1—melanoma	4.88e-05	6.94e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CDKN1B—melanoma	4.86e-05	6.9e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CD—melanoma	4.85e-05	6.89e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CB—melanoma	4.84e-05	6.87e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—AKT1—melanoma	4.83e-05	6.87e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ERBB2—melanoma	4.82e-05	6.85e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—BRAF—melanoma	4.82e-05	6.85e-05	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—AKT1—melanoma	4.81e-05	6.83e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	4.8e-05	6.83e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CASP3—melanoma	4.76e-05	6.77e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CB—melanoma	4.76e-05	6.76e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL2—melanoma	4.75e-05	6.76e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—KRAS—melanoma	4.75e-05	6.75e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—IL6—melanoma	4.73e-05	6.72e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CB—melanoma	4.7e-05	6.68e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IGF1—melanoma	4.69e-05	6.67e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—MAPK1—melanoma	4.67e-05	6.64e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—EGFR—melanoma	4.67e-05	6.64e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTGS2—melanoma	4.65e-05	6.61e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CXCL8—melanoma	4.65e-05	6.6e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—FGF2—melanoma	4.64e-05	6.6e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCND1—melanoma	4.63e-05	6.59e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—HRAS—melanoma	4.62e-05	6.56e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CTNNB1—melanoma	4.59e-05	6.52e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CXCL8—melanoma	4.57e-05	6.5e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—HRAS—melanoma	4.54e-05	6.46e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CDKN1B—melanoma	4.54e-05	6.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MAP2K1—melanoma	4.54e-05	6.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CD—melanoma	4.51e-05	6.4e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MMP9—melanoma	4.5e-05	6.39e-05	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—AKT1—melanoma	4.49e-05	6.38e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CDKN1A—melanoma	4.48e-05	6.37e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—VEGFA—melanoma	4.48e-05	6.36e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PTEN—melanoma	4.47e-05	6.36e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CDKN1B—melanoma	4.47e-05	6.35e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	4.46e-05	6.34e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NFKB1—melanoma	4.45e-05	6.33e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CASP3—melanoma	4.45e-05	6.32e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL2—melanoma	4.44e-05	6.31e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—STAT3—melanoma	4.43e-05	6.3e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—NRAS—melanoma	4.42e-05	6.28e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—IL6—melanoma	4.42e-05	6.28e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—AKT1—melanoma	4.42e-05	6.28e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—KRAS—melanoma	4.41e-05	6.27e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CASP3—melanoma	4.38e-05	6.22e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL2—melanoma	4.37e-05	6.21e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—AKT1—melanoma	4.36e-05	6.2e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	4.36e-05	6.2e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—IL6—melanoma	4.35e-05	6.18e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MDM2—melanoma	4.34e-05	6.17e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCND1—melanoma	4.33e-05	6.15e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—FGF2—melanoma	4.31e-05	6.13e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CTNNB1—melanoma	4.29e-05	6.09e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ERBB2—melanoma	4.28e-05	6.09e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCND1—melanoma	4.26e-05	6.05e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MAPK3—melanoma	4.23e-05	6.02e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CB—melanoma	4.23e-05	6.01e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CTNNB1—melanoma	4.22e-05	6e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MMP9—melanoma	4.2e-05	5.97e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CDKN1A—melanoma	4.19e-05	5.95e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PTEN—melanoma	4.18e-05	5.94e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NFKB1—melanoma	4.16e-05	5.91e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MMP9—melanoma	4.14e-05	5.88e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CDKN1A—melanoma	4.12e-05	5.86e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MYC—melanoma	4.12e-05	5.85e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PTEN—melanoma	4.11e-05	5.84e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NFKB1—melanoma	4.09e-05	5.82e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—AKT1—melanoma	4.08e-05	5.79e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CXCL8—melanoma	4.06e-05	5.77e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTEN—melanoma	4.06e-05	5.77e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	4.05e-05	5.76e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—VEGFA—melanoma	4.04e-05	5.74e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MDM2—melanoma	4.04e-05	5.74e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—HRAS—melanoma	4.04e-05	5.74e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MAPK1—melanoma	4.03e-05	5.72e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EGFR—melanoma	4.03e-05	5.72e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—AKT1—melanoma	4.01e-05	5.7e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—STAT3—melanoma	4e-05	5.69e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NRAS—melanoma	3.99e-05	5.67e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ERBB2—melanoma	3.98e-05	5.66e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CDKN1B—melanoma	3.97e-05	5.64e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CB—melanoma	3.93e-05	5.58e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—AKT1—melanoma	3.92e-05	5.58e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CASP3—melanoma	3.89e-05	5.53e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL2—melanoma	3.88e-05	5.52e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—IL6—melanoma	3.86e-05	5.49e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MAPK3—melanoma	3.82e-05	5.43e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—KRAS—melanoma	3.8e-05	5.41e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCND1—melanoma	3.78e-05	5.38e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CXCL8—melanoma	3.77e-05	5.36e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—VEGFA—melanoma	3.77e-05	5.36e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—HRAS—melanoma	3.75e-05	5.33e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CTNNB1—melanoma	3.75e-05	5.33e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—STAT3—melanoma	3.74e-05	5.31e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NRAS—melanoma	3.73e-05	5.3e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MYC—melanoma	3.72e-05	5.28e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—VEGFA—melanoma	3.71e-05	5.28e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	3.69e-05	5.24e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—STAT3—melanoma	3.68e-05	5.23e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MMP9—melanoma	3.67e-05	5.22e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NRAS—melanoma	3.67e-05	5.21e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CDKN1A—melanoma	3.66e-05	5.2e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PTEN—melanoma	3.65e-05	5.19e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	3.65e-05	5.18e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MAPK1—melanoma	3.64e-05	5.17e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EGFR—melanoma	3.64e-05	5.17e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NFKB1—melanoma	3.64e-05	5.17e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CASP3—melanoma	3.61e-05	5.13e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL2—melanoma	3.61e-05	5.13e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—IL6—melanoma	3.59e-05	5.1e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MAPK3—melanoma	3.57e-05	5.07e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—AKT1—melanoma	3.56e-05	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CA—melanoma	3.53e-05	5.01e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCND1—melanoma	3.52e-05	5e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MAPK3—melanoma	3.51e-05	4.99e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CA—melanoma	3.5e-05	4.97e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	3.48e-05	4.95e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MYC—melanoma	3.47e-05	4.93e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—KRAS—melanoma	3.43e-05	4.88e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MYC—melanoma	3.42e-05	4.86e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MMP9—melanoma	3.41e-05	4.85e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	3.4e-05	4.83e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MAPK1—melanoma	3.4e-05	4.83e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EGFR—melanoma	3.4e-05	4.83e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PTEN—melanoma	3.39e-05	4.82e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TP53—melanoma	3.38e-05	4.81e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NFKB1—melanoma	3.38e-05	4.8e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MAPK1—melanoma	3.34e-05	4.75e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EGFR—melanoma	3.34e-05	4.75e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AKT1—melanoma	3.31e-05	4.71e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—VEGFA—melanoma	3.3e-05	4.69e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—STAT3—melanoma	3.27e-05	4.64e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NRAS—melanoma	3.26e-05	4.63e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HRAS—melanoma	3.23e-05	4.6e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—KRAS—melanoma	3.21e-05	4.56e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—KRAS—melanoma	3.16e-05	4.49e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CA—melanoma	3.16e-05	4.48e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MAPK3—melanoma	3.12e-05	4.44e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL6—melanoma	3.1e-05	4.4e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—VEGFA—melanoma	3.07e-05	4.36e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TP53—melanoma	3.05e-05	4.34e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MYC—melanoma	3.04e-05	4.31e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—STAT3—melanoma	3.04e-05	4.31e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NRAS—melanoma	3.03e-05	4.3e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MAPK1—melanoma	2.97e-05	4.22e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGFR—melanoma	2.97e-05	4.22e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CA—melanoma	2.95e-05	4.19e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HRAS—melanoma	2.92e-05	4.15e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CA—melanoma	2.9e-05	4.12e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MAPK3—melanoma	2.9e-05	4.12e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AKT1—melanoma	2.88e-05	4.09e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CA—melanoma	2.86e-05	4.07e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKT1—melanoma	2.86e-05	4.06e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TP53—melanoma	2.85e-05	4.05e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MYC—melanoma	2.82e-05	4.01e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TP53—melanoma	2.81e-05	3.99e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—KRAS—melanoma	2.8e-05	3.99e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL6—melanoma	2.79e-05	3.97e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MAPK1—melanoma	2.76e-05	3.92e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGFR—melanoma	2.76e-05	3.92e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HRAS—melanoma	2.73e-05	3.88e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HRAS—melanoma	2.68e-05	3.81e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL6—melanoma	2.61e-05	3.71e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KRAS—melanoma	2.61e-05	3.7e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKT1—melanoma	2.58e-05	3.66e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.58e-05	3.66e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL6—melanoma	2.57e-05	3.65e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TP53—melanoma	2.49e-05	3.54e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKT1—melanoma	2.41e-05	3.42e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	2.39e-05	3.4e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HRAS—melanoma	2.38e-05	3.39e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT1—melanoma	2.37e-05	3.37e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AKT1—melanoma	2.34e-05	3.32e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TP53—melanoma	2.32e-05	3.29e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL6—melanoma	2.28e-05	3.24e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HRAS—melanoma	2.22e-05	3.15e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL6—melanoma	2.12e-05	3.01e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT1—melanoma	2.11e-05	2.99e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT1—melanoma	1.96e-05	2.78e-05	CbGpPWpGaD
